This study planned to update the previous investigations and researches related to this matter in order to fuse new discoveries. Among preliminaries that evaluated drug classes or methodologies related with weight reduction (concentrated way of life changes, GLP-1 receptor agonists, or SGLT2 inhibitors), the danger decrease for MACE was steady among members with (0·87, 0·83–0·92) and without (0·92, 0·83–1·02) set up cardiovascular illness at gauge (p interaction=0·33). For cardiovascular breakdown, the RR for drug classes or procedures related with weight reduction was steady among members with (0·80, 0·73–0·89) and without (0·84, 0·74–0·95) cardiovascular sickness at gauge (p interaction=0·63).
The investigation included randomized controlled preliminaries with at least 1000 grown-ups (matured ≥19 years) with or in danger of type 2 diabetes, with major antagonistic cardiovascular occasions (MACE) as a result, and with development of in any event a year.
The updated search yielded 30 eligible trials (n=225 305). The mean age of participants was 63·0 years (SD 8·4) and mean duration of diabetes was 9·4 years (6·6).
As a conclusion it is evident that, Glucose-lowering drugs or strategies overall reduced the risk of fatal and non-fatal atherosclerotic events. After a mean follow-up of 3·8 years (1·8), 23 016 (10·2%) participants had MACE and 8169 (3·6%) had a heart failure event. Glucose-lowering drugs or strategies lowered the risk of MACE compared with standard care or placebo (RR 0·92, 95% CI 0·89–0·95, p<0·0001), with no overall effect on the risk of heart failure (0·98, 0·90–1·08, p=0·71).
Ref: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30038-3/fulltext
